4.820
0.000
(0.00%)
At close: January 28 at 12:08:04 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-444,727.000
-444,727.000
-343,897.000
-169,741.000
-122,853.000
Investing Cash Flow
378,524.000
378,524.000
-216,575.000
-1,459,725.000
-5,955.000
Financing Cash Flow
-16,105.000
-16,105.000
-20,814.000
2,101,859.000
505,890.000
End Cash Position
578,081.000
578,081.000
641,837.000
1,063,857.000
617,773.000
Capital Expenditure
-12,251.000
-12,251.000
-22,746.000
-12,335.000
-4,034.000
Issuance of Capital Stock
8,418.000
8,418.000
3,740.000
2,228,168.000
510,975.000
Repurchase of Capital Stock
-12,908.000
-12,908.000
-4,055.000
--
--
Free Cash Flow
-456,978.000
-456,978.000
-366,643.000
-182,076.000
-126,887.000
12/31/2020 - 10/15/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1530.HK 3SBIO
6.010
-3.22%
ADAG Adagene Inc.
1.9000
+2.70%
2269.HK WuXi Biologics (Cayman) Inc.
18.420
-0.22%
KYMR Kymera Therapeutics, Inc.
39.59
-2.13%
NUVB Nuvation Bio Inc.
2.3100
-3.75%
RPRX Royalty Pharma plc
31.58
-0.03%
LXRX Lexicon Pharmaceuticals, Inc.
0.7562
-7.71%
XFOR X4 Pharmaceuticals, Inc.
0.7001
+5.74%
DNA Ginkgo Bioworks Holdings, Inc.
13.36
-3.95%